Oliver P Flint

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. pmc The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications
    Oliver P Flint
    Pharmaceutical Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    Toxicol Pathol 37:65-77. 2009
  2. ncbi Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically
    Mustafa A Noor
    Discovery and Exploratory Clinical Research, Bristol Myers Squibb Company, NJ 08543, USA
    AIDS 20:1813-21. 2006
  3. ncbi Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors
    Rex A Parker
    Metabolic and Cardiovascular Discovery Biology, Bristol Myers Squibb Pharmaceutical Research Institute, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    Mol Pharmacol 67:1909-19. 2005
  4. doi Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    Wei Meng
    Drug Safety Evaluation and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    J Med Chem 51:1145-9. 2008
  5. doi Establishment of a molecular embryonic stem cell developmental toxicity assay
    Julieta M Panzica-Kelly
    Discovery Toxicology, Bristol Myers Squibb Company, Pennington, NJ 08534, USA
    Toxicol Sci 131:447-57. 2013

Detail Information

Publications5

  1. pmc The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications
    Oliver P Flint
    Pharmaceutical Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    Toxicol Pathol 37:65-77. 2009
    ..This process leads to a pathologic cycle of lipotoxicity and lipoatrophy and a clinical phenotype of body fat distribution with elevated waist-to-hip ratio similar to the metabolic syndrome...
  2. ncbi Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically
    Mustafa A Noor
    Discovery and Exploratory Clinical Research, Bristol Myers Squibb Company, NJ 08543, USA
    AIDS 20:1813-21. 2006
    ..The HIV protease inhibitor (PI) atazanavir does not impair insulin sensitivity acutely but ritonavir and lopinavir induce insulin resistance at therapeutic concentrations...
  3. ncbi Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors
    Rex A Parker
    Metabolic and Cardiovascular Discovery Biology, Bristol Myers Squibb Pharmaceutical Research Institute, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    Mol Pharmacol 67:1909-19. 2005
    ....
  4. doi Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    Wei Meng
    Drug Safety Evaluation and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    J Med Chem 51:1145-9. 2008
    ..These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes...
  5. doi Establishment of a molecular embryonic stem cell developmental toxicity assay
    Julieta M Panzica-Kelly
    Discovery Toxicology, Bristol Myers Squibb Company, Pennington, NJ 08534, USA
    Toxicol Sci 131:447-57. 2013
    ..The false positive rate in the training and test sets was 24 and 0%, respectively, indicating that this assay has potential to identify teratogens...